Monday, September 21, 2026

Moderna Stock Over 9% Down So Far Today

ViaNews Editorial Team

December 22, 2020

Moderna Stock Over 9% Down So Far Today

Shares of Moderna fell 9.81% to $124.74 at 14:50 EST on Tuesday, after two successive sessions in a row of losses. The Nasdaq Stock Market is jumping 0.48% to $12,804.00, after two consecutive sessions in a row of losses. This seems, up to now, a somewhat positive trend trading session today.

Moderna's last close was $138.30, 43.10% under its 52-week high of $178.50.

Moderna's Sales

Moderna's sales growth is 1841.7% for the present quarter and 19117.5% for the next. The company's growth estimates for the present quarter is a negative 2.7% and positive 660% for the next.

Moderna's Revenue

Year-on-year quarterly revenue growth grew by 826.4%, now sitting on 246.7M for the twelve trailing months.

Moderna's Stock Yearly Top and Bottom Value

Moderna's stock is valued at $124.74 at 14:50 EST, way under its 52-week high of $178.50 and way higher than its 52-week low of $17.68.

Moderna's Moving Average

Moderna's value is higher than its 50-day moving average of $116.47 and way higher than its 200-day moving average of $80.87.

Previous days news about Moderna

Moderna shot cleared in U.S., boosting immunization effort. According to Bloomberg Quint on Sat Dec 19, "Overall, Moderna and manufacturing partner Lonza Group AG plan to produce 500 million to 1 billion total doses of its vaccine in 2021. ", "Developed with the National Institutes of Health, Moderna's shot, like the one produced by Pfizer Inc. and BioNTech SE that was cleared last week, is based on messenger RNA technology that previously hadn't been used in vaccines. "

Moderna, Exxon, Alphabet, Amazon: stocks that defined the week. According to The Wall Street Journal on Sat Dec 19, "Moderna, a ten-year-old biotech that has never had a product cleared by the FDA, expects to deliver a total of 20 million doses by the end of December. ", "U.S. health regulators late Friday permitted use of Moderna's Covid-19 vaccine, the second shot to get the green light to help end the pandemic. "

Statement on the U.S. authorization of the Moderna Covid-19 vaccine. According to Business Insider on Sat Dec 19, "Health Canada has been reviewing Moderna's vaccine since it was submitted on October 12, 2020, and is expediting the review of COVID-19 vaccines. ", "OTTAWA, ON, Dec. 18, 2020 /CNW/ -Health Canada is aware that the U.S. Food and Drug Administration has issued an emergency use authorization for a COVID-19 vaccine manufactured by Moderna."

Moderna to begin delivery; London lockdown ordered: virus update. According to Bloomberg Quint on Sat Dec 19, "That allocation will bolster the 55.8 million doses that it will receive through a European Union plan, with a further 50.5 million doses of the Moderna Inc. due from the EU. ", "United Parcel Services will truck the newly-approved Moderna vaccine beginning Sunday morning from Mckesson's Kentucky facility to the courier's nearby main U.S. air hub in Louisville, Kentucky. "

Philippines to start vaccine talks with Moderna by year-end: CNN. According to Bloomberg Quint on Mon Dec 21, "The Philippines will start talks with Moderna Inc. on or before Dec. 30 to secure supply of the company's coronavirus vaccine, Foreign Affairs Secretary Teodoro Locsin said Monday.", ""Moderna is interested in giving an allocation," he said in a live-streamed interview with CNN Philippines, citing Philippine ambassador to the U.S. Jose Manuel Romualdez."

In this story · Knowledge Files

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Frontier AI Slowdown Call Splits Industry, Rattles Capex-Sensitive Markets
Anthropic's Dario Amodei publicly called for a coordinated global slowdown in frontier AI development, a stance Microsoft echoed with a 'humanist' AI code of conduct, but Nvidia and Meta's CEOs rejected any coordinated pause days later, exposing a widening rift between safety-focused and growth-focused AI leaders. The dispute landed amid growing financial scrutiny of AI infrastructure spending — a hyperscaler capex analysis, FTC warnings against antitrust waivers for AI firms, and an 8.6% single-day stock drop in GE Vernova tied directly to the slowdown remarks — signaling investors are newly nervous about whether the AI capex boom (including Alphabet's projected $701B revenue narrative) can be justified if the pace of development itself becomes contested.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,983
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,983 facts checked against source5,304 source documents archived
Query this data → isubstrate.com